A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis

Nature Chemical Biology

Volumn 7, Issue 6, 2011, Pages 375-383

  Chidley, Christopher ^a   Haruki, Hirohito ^a   Pedersen, Miriam GrØnlund ^a   Muller, Evelyne ^a   Johnsson, Kai ^a  

^a The National Centre of Competence in Research (NCCR)   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; DIHYDROFOLATE REDUCTASE; ERLOTINIB; FUROSEMIDE; INDOMETACIN; MESALAZINE; METHOTREXATE; PHOSPHODIESTERASE; PURVALANOL B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SALAZOSULFAPYRIDINE; SEPIAPTERIN REDUCTASE; SULFAPYRIDINE; TETRAHYDROBIOPTERIN;

ANOREXIA; ARTICLE; BACTERIAL GROWTH; BACTERIUM COLONY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; ENZYME KINETICS; ESCHERICHIA COLI; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RHEUMATOID ARTHRITIS; SACCHAROMYCES CEREVISIAE; ULCERATIVE COLITIS; VOMITING;

EID: 85027931231     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.557     Document Type: Article

References (50)

1. Terstappen, G.C., Schlupen, C., Raggiaschi, R. & Gaviraghi, G. Target deconvolution strategies in drug discovery. Nat. Rev. Drug Discov. 6, 891-903 (2007). (Pubitemid 350042397)
2. Chan, J.N., Nislow, C. & Emili, A. Recent advances and method development for drug target identification. Trends Pharmacol. Sci. 31, 82-88 (2010).
3. Rix, U. & Superti-Furga, G. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 5, 616-624 (2009).
4. Licitra, E.J. & Liu, J.O. A three-hybrid system for detecting small ligand-protein receptor interactions. Proc. Natl. Acad. Sci. USA 93, 12817-12821 (1996). (Pubitemid 26382726)
5. Becker, F. et al. A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. Chem. Biol. 11, 211-223 (2004). (Pubitemid 38300291)
6. Keppler, A. et al. A general method for the covalent labeling of fusion proteins with small molecules in vivo. Nat. Biotechnol. 21, 86-89 (2003). (Pubitemid 36055833)
7. Kolaczkowski, M., Kolaczowska, A., Luczynski, J., Witek, S. & Goffeau, A. In vivo characterization of the drug resistance profile of the major ABC transporters and other components of the yeast pleiotropic drug resistance network. Microb. Drug Resist. 4, 143-158 (1998). (Pubitemid 28500712)
8. McMurray, M.A. & Thorner, J. Septin stability and recycling during dynamic structural transitions in cell division and development. Curr. Biol. 18, 1203-1208 (2008).
9. Bolin, J.T., Filman, D.J., Matthews, D.A., Hamlin, R.C. & Kraut, J. Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexate. J. Biol. Chem. 257, 13650-13662 (1982). (Pubitemid 13187127)
10. Gendreizig, S., Kindermann, M. & Johnsson, K. Induced protein dimerization in vivo through covalent labeling. J. Am. Chem. Soc. 125, 14970-14971 (2003). (Pubitemid 37509646)
11. Mayer, R.J., Chen, J.T., Taira, K., Fierke, C.A. & Benkovic, S.J. Importance of a hydrophobic residue in binding and catalysis by dihydrofolate reductase. Proc. Natl. Acad. Sci. USA 83, 7718-7720 (1986). (Pubitemid 17183918)
12. Murphy, D.J. & Benkovic, S.J. Hydrophobic interactions via mutants of Escherichia coli dihydrofolate reductase: Separation of binding and catalysis. Biochemistry 28, 3025-3031 (1989). (Pubitemid 19099486)
13. Koegl, M. & Uetz, P. Improving yeast two-hybrid screening systems. Brief. Funct. Genomics Proteomics 6, 302-312 (2008).
14. Vidalain, P.O., Boxem, M., Ge, H., Li, S. & Vidal, M. Increasing specificity in high-throughput yeast two-hybrid experiments. Methods 32, 363-370 (2004). (Pubitemid 38299327)
15. Fromont-Racine, M., Rain, J.C. & Legrain, P. Toward a functional analysis of the yeast genome through exhaustive two-hybrid screens. Nat. Genet. 16, 277-282 (1997). (Pubitemid 27280212)
16. Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
17. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044 (2007). (Pubitemid 47517638)
18. Rix, U. et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110, 4055-4063 (2007). (Pubitemid 350248462)
19. Stamos, J., Sliwkowski, M.X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265-46272 (2002). (Pubitemid 35417619)
20. Fairn, G.D. & McMaster, C.R. Emerging roles of the oxysterol-binding protein family in metabolism, transport, and signaling. Cell. Mol. Life Sci. 65, 228-236 (2008). (Pubitemid 351161484)
21. Istvan, E.S. & Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160-1164 (2001). (Pubitemid 32440937)
22. Lockhart, D.J. et al. Pyrrole compounds and uses thereof. Vol. US 7.323.490 B2 (Ambit BioSciences Corporation, 2008).
23. Wilson, S.J. & Smyth, E.M. Internalization and recycling of the human prostacyclin receptor is modulated through its isoprenylation-dependent interaction with the delta subunit of cGMP phosphodiesterase 6. J. Biol. Chem. 281, 11780-11786 (2006). (Pubitemid 43855437)
24. Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A. & Landreth, G. Mechanisms of statin-mediated inhibition of small G-protein function. J. Biol. Chem. 280, 34202-34209 (2005). (Pubitemid 41443145)
25. Winger, J.A., Hantschel, O., Superti-Furga, G. & Kuriyan, J. The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct. Biol. 9, 7 (2009).
26. Caprilli, R., Cesarini, M., Angelucci, E. & Frieri, G. The long journey of salicylates in ulcerative colitis: The past and the future. J. Crohn's Colitis 3, 149-156 (2009).
27. Rousseaux, C. et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J. Exp. Med. 201, 1205-1215 (2005). (Pubitemid 40629065)
28. Sutherland, L. & Macdonald, J.K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. CD000544 (2006).
29. Baggott, J.E., Morgan, S.L., Ha, T., Vaughn, W.H. & Hine, R.J. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem. J. 282, 197-202 (1992).
30. Wahl, C., Liptay, S., Adler, G. & Schmid, R.M. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest. 101, 1163-1174 (1998). (Pubitemid 28125296)
31. Thöny, B., Auerbach, G. & Blau, N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J. 347, 1-16 (2000). (Pubitemid 30199034)
32. Smith, G.K., Duch, D.S., Edelstein, M.P. & Bigham, E.C. New inhibitors of sepiapterin reductase. Lack of an effect of intracellular tetrahydrobiopterin depletion upon in vitro proliferation of two human cell lines. J. Biol. Chem. 267, 5599-5607 (1992).
33. Dahan, A. & Amidon, G.L. MRP2 mediated drug-drug interaction: Indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int. J. Pharm. 386, 216-220 (2010).
34. Gross, S.S. & Levi, R. Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. J. Biol. Chem. 267, 25722-25729 (1992). (Pubitemid 23013967)
35. Bune, A.J. et al. Inhibition of tetrahydrobiopterin synthesis reduces in vivo nitric oxide production in experimental endotoxic shock. Biochem. Biophys. Res. Commun. 220, 13-19 (1996). (Pubitemid 26106791)
36. Farrell, A.J., Blake, D.R., Palmer, R.M. & Moncada, S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann. Rheum. Dis. 51, 1219-1222 (1992).
37. Singer, I.I. et al. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 111, 871-885 (1996). (Pubitemid 26327590)
38. Connor, J.R. et al. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur. J. Pharmacol. 273, 15-24 (1995).
39. Kankuri, E. et al. Suppression of acute experimental colitis by a highly selective inducible nitric-oxide synthase inhibitor, N-[3-(aminomethyl)benzyl] acetamidine. J. Pharmacol. Exp. Ther. 298, 1128-1132 (2001). (Pubitemid 32761929)
40. Farr, M., Brodrick, A. & Bacon, P.A. Plasma and synovial fluid concentrations of sulphasalazine and two of its metabolites in rheumatoid arthritis. Rheumatol. Int. 5, 247-251 (1985). (Pubitemid 16232307)
41. Pullar, T., Hunter, J.A. & Capell, H.A. Which component of sulphasalazine is active in rheumatoid arthritis? Br. Med. J. (Clin. Res. Ed.) 290, 1535-1538 (1985). (Pubitemid 15094508)
42. Lauritsen, K., Hansen, J., Ryde, M. & Rask-Madsen, J. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology 86, 1496-1500 (1984). (Pubitemid 14147943)
43. Klotz, U. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Dig. Liver Dis. 37, 381-388 (2005). (Pubitemid 44356040)
44. Temperini, C., Cecchi, A., Scozzafava, A. & Supuran, C.T. Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg. Med. Chem. 17, 1214-1221 (2009).
45. Gierse, J.K., Koboldt, C.M., Walker, M.C., Seibert, K. & Isakson, P.C. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem. J. 339, 607-614 (1999). (Pubitemid 29243524)
46. Hori, T. et al. Crystal structure of anti-configuration of indomethacin and leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase complex reveals the structural basis of broad spectrum indomethacin efficacy. J. Biochem. 140, 457-466 (2006). (Pubitemid 44703165)
47. Tegeder, I. et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat. Med. 12, 1269-1277 (2006). (Pubitemid 44706929)
48. Lötsch, J., Klepstad, P., Doehring, A. & Dale, O.A. GTP cyclohydrolase 1 genetic variant delays cancer pain. Pain 148, 103-106 (2010).
49. Berti-Mattera, L.N., Kern, T.S., Siegel, R.E., Nemet, I. & Mitchell, R. Sulfasalazine blocks the development of tactile allodynia in diabetic rats. Diabetes 57, 2801-2808 (2008).
50. Blau, N., Bonafe, L. & Thony, B. Tetrahydrobiopterin deficiencies without hyperphenylalaninemia: Diagnosis and genetics of dopa-responsive dystonia and sepiapterin reductase deficiency. Mol. Genet. Metab. 74, 172-185 (2001). (Pubitemid 32955158)